Workflow
药明康德(603259):2024年报点评:业绩逐季提升,在手订单高速增长

Investment Rating - The report maintains a "Buy" rating for WuXi AppTec [6] Core Views - The company has shown a quarter-on-quarter improvement in performance, with a significant increase in backlog orders, which grew by 47% year-on-year to 49.31 billion yuan [10] - The new molecule business (TIDES) has experienced rapid growth, with a year-on-year revenue increase of 57.2%, driven by strong market demand and the company's enhanced capabilities [10] - The company is expected to return to double-digit revenue growth in 2025, supported by robust order backlog and incentive plans for H-share awards [10] Financial Performance Summary - For 2023, the company reported revenue of 40.34 billion yuan, a year-on-year growth of 2.5%, while the adjusted net profit was 9.61 billion yuan, reflecting a 9% increase [5] - The projected revenue for 2025 is 42.46 billion yuan, with an expected net profit of 10.51 billion yuan, indicating a growth of 11.3% [3][5] - The gross margin is expected to improve to 43.5% in 2025, while the net margin is projected to be 24.8% [5] Valuation and Price Target - The report estimates a reasonable valuation for the company at a price-to-earnings ratio of 29 times for 2025, leading to a target price of 105.56 yuan [3] - The current share price is noted at 68 yuan as of March 27, 2025 [6] Market Performance - The stock has shown a 49.64% increase over the past 12 months, outperforming the market [7]